Integra Lifesciences Holdings (IART) Gross Profit (2009 - 2026)

Integra Lifesciences Holdings' Gross Profit history runs 18 years deep, the most recent figure standing at $217.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 11.6% year-over-year to $217.0 million; the TTM figure through Mar 2026 stood at $854.2 million (down 1.78% YoY), while the FY2025 annual figure was $831.6 million, down 5.72% from the prior year.
• Gross Profit came in at $217.0 million for Q1 2026 at Integra Lifesciences Holdings, down from $220.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $250.1 million in Q4 2022 to a low of $194.4 million in Q1 2025.
• A 5-year average of $222.7 million and a median of $220.9 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit dropped 16.99% in 2023 and climbed 11.6% in 2026, its largest moves.
• Integra Lifesciences Holdings' Gross Profit stood at $250.1 million in 2022, then declined by 9.43% to $226.5 million in 2023, then gained by 9.97% to $249.1 million in 2024, then decreased by 11.32% to $220.9 million in 2025, then decreased by 1.76% to $217.0 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $217.0 million, $220.9 million, and $207.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison